Hospitalizations and death are more common among these patients than clinicians might think. 

This new measurement, researchers explained, can help clinicians target high-risk patients with more aggressive treatments. 

“Given the potential morbidity of COVID-19 infection even in younger adults, the risk-benefit decision for vaccination remains highly favorable," researchers wrote.

The SGLT2 inhibitor was approved for this new indication based on results from the EMPEROR-Reduced trial.

"This is a very important advance in the field of cell therapy and in the management of heart failure," one specialist said. 

The device's internal pump was associated with a heightened risk of adverse outcomes, including stroke and death. 

Patients with chronic kidney disease face an especially high risk of developing new-onset heart failure after discharge. 

Researchers believe they have found the first blood biomarker for diagnosing myocarditis, sharing their findings in the New England Journal of Medicine.

In a recent advisory, the FDA specifically mentioned Abbott's HeartMate 3 LVAD as an effective alternative to Medtronic's HVAD system.